Identification of potent P2Y‐purinoceptor agonists that are derivatives of adenosine 5′‐monophosphate
Open Access
- 1 August 1996
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 118 (8) , 1959-1964
- https://doi.org/10.1111/j.1476-5381.1996.tb15630.x
Abstract
1 A series of chain-extended 2-thioether derivatives of adenosine monophosphate were synthesized and tested as agonists for activation of the phospholipase C-linked P2Y-purinoceptor of turkey erythrocyte membranes, the adenylyl cyclase-linked P2Y-purinoceptor of C6 rat glioma cells, and the cloned human P2U-receptor stably expressed in 1321N1 human astrocytoma cells. 2 Although adenosine monophosphate itself was not an agonist in the two P2Y-purinoceptor test systems, eleven different 2-thioether-substituted adenosine monophosphate analogues were full agonists. The most potent of these agonists, 2-hexylthio AMP, exhibited an EC50 value of 0.2 nM for activation of the C6 cell receptor. This potency was 16,000 fold greater than that of ATP and was only 10 fold less than the potency of 2-hexylthio ATP in the same system. 2-hexylthio adenosine was inactive. 3 Monophosphate analogues that were the most potent activators of the C6 cell P2Y-purinoceptor were also the most potent activators of the turkey erythrocyte P2Y-purinoceptor. However, agonists were in general more potent at the C6 cell receptor, and potency differences varied between 10 fold and 300 fold between the two receptors. 4 Although 2-thioether derivatives of adenosine monophosphate were potent P2Y-purinoceptor agonists no effect of these analogues on the human P2U-purinoceptor were observed. 5 These results support the view that a single monophosphate is sufficient and necessary for full agonist activity at P2Y-purinoceptors, and provide insight for strategies for development of novel P2Y-purinoceptor agonists of high potency and selectivity.Keywords
This publication has 24 references indexed in Scilit:
- Is there a basis for distinguishing two types of P2-purinoceptor?Published by Elsevier ,2002
- Second messenger cascade specificity and pharmacological selectivity of the human P2Y1‐purinoceptorBritish Journal of Pharmacology, 1996
- Potent agonist action of 2‐thioether derivatives of adenine nucleotides at adenylyl cyclase‐linked P2y‐purinoceptorsBritish Journal of Pharmacology, 1995
- Pharmacological selectivity of the cloned human P2U‐purinoceptor: potent activation by diadenosine tetraphosphateBritish Journal of Pharmacology, 1995
- P2-Purinergic Receptors: Subtype-Associated Signaling Responses and StructureAnnual Review of Pharmacology and Toxicology, 1995
- Differential effects of P2‐purinoceptor antagonists on phospholipase C‐ and adenylyl cyclase‐coupled P2Y‐purinoceptorsBritish Journal of Pharmacology, 1994
- Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy.Proceedings of the National Academy of Sciences, 1994
- Structure activity relationships for derivatives of adenosine‐5′‐triphosphate as agonists at P2 purinoceptors: Heterogeneity within P2x and P2y subtypesDrug Development Research, 1994
- Cloning and functional expression of a brain G‐protein‐coupled ATP receptorFEBS Letters, 1993
- Expression cloning of an ATP receptor from mouse neuroblastoma cells.Proceedings of the National Academy of Sciences, 1993